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Colocalization of Cell Death with Antigen Deposition
in Skin Enhances Vaccine Immunogenicity
Alexandra C.I. Depelsenaire1, Stefano C. Meliga1, Celia L. McNeilly1, Frances E. Pearson1, Jacob W. Coffey1,
Oscar L. Haigh1, Christopher J. Flaim1, Ian H. Frazer2 and Mark A.F. Kendall1,2,3
Vaccines delivered to the skin by microneedles—with and without adjuvants—have increased immunogenicity
with lower doses than standard vaccine delivery techniques such as intramuscular or intradermal injection.
However, the mechanisms underlying this skin-mediated ‘‘adjuvant’’ effect are not clear. Here, we show that the
dynamic application of a microprojection array (the Nanopatch) to skin generates localized transient stresses
invoking cell death around each projection. Nanopatch application caused significantly higher levels (B65-fold)
of cell death in murine ear skin than i.d. injection using a hypodermic needle. Measured skin cell death is
associated with modeled stresses B1–10 MPa. Nanopatch-immunized groups also yielded consistently higher
anti-immunoglobulin G endpoint titers (up to 50-fold higher) than i.d. groups after delivery of a split virion
influenza vaccine. Importantly, colocalization of cell death with nearby live skin cells and delivered antigen was
necessary for immunogenicity enhancement. These results suggest a correlation between cell death caused by
the Nanopatch with increased immunogenicity. We propose that the localized cell death serves as a ‘‘physical
immune enhancer’’ for the adjacent viable skin cells, which also receive antigen from the projections. This natural
immune enhancer effect has the potential to mitigate or replace chemical-based adjuvants in vaccines.
Journal of Investigative Dermatology (2014) 134, 2361–2370; doi:10.1038/jid.2014.174; published online 8 May 2014
INTRODUCTION
As conventional vaccine delivery techniques such as intra-
muscular (i.m.) and subcutaneous injections bypass the skin’s
immune cells, the skin has increasingly become the target for
vaccine delivery (Gutowska-Owsiak and Ogg, 2012; Jiang
et al., 2012; Kupper, 2012). Immunizations via skin by
intradermal (i.d.) injection have demonstrated similar or
improved immunogenicity with commonly reported B5- to
10-fold dose-sparing, i.e., a significant reduction of antigen
required to elicit equivalent immunogenicity compared with
other needle-based vaccinations such as i.m. injections
against influenza (Belshe et al., 2004; Kenney et al., 2004;
Auewarakul et al., 2007; Van Damme et al., 2009; Quan
et al., 2010; Hung et al., 2012a), compared with standard i.m.
routes. However, difficulties exist in effectively and
consistently delivering vaccines into the skin. Therefore, new
cutaneous vaccine delivery devices such as microneedles and
the Nanopatch (NP) have been developed (Chen et al., 2009;
Kim et al., 2012a; Koutsonanos et al., 2013), which may
also reduce needle-stick injuries, disease transmission of
blood-borne diseases (Ekwueme et al., 2002), and could
allow for self-administration (Prausnitz et al., 2009). In our
previous work, delivery of a conventional influenza vaccine
by NP to skin with antigen alone has achieved B100-fold
dose-sparing compared with i.m. delivery (Fernando et al.,
2010), whereas co-delivery of adjuvant generated syner-
gistically improved antibody and T-cell immune responses
(Fernando et al., 2012; Ng et al., 2012).
The NP is a microprojection array with 420,000 cm 2
100-mm-long projections (illustrated in Figure 1a and b) that is
applied onto skin at 2.3m s1 using a spring-loaded applica-
tor, ensuring consistent penetration across the array (Crichton
et al., 2010). Although i.d. injection deposits vaccine within
the vicinity of dermal antigen-presenting cells, previous
studies showed that the NP deposits antigen into both the
viable epidermis (VE) and dermis (Fernando et al., 2010).
A contributing factor to improved immunogenicity may be in
the mechanical interaction of the NP with the skin. Recently,
we have shown that NP projections impacting upon the skin
and decelerating upon penetration generate significant stresses
within the skin (up to 50 MPa) within an B20mm radius
around each projection (Meliga et al., 2013). We postulated
that such stresses invoke localized cell death and inflamma-
tion in the skin, contributing to the improved immune
ORIGINAL ARTICLE
1D2G2, The Australian Institute for Bioengineering and Nanotechnology, The
University of Queensland, St Lucia, Queensland, Australia; 2The University of
Queensland, Diamantina Institute for Cancer, Brisbane, Queensland, Australia
and 3Faculty of Medicine and Biomedical Sciences, The University of
Queensland, Centre for Clinical Research, Royal Brisbane and Women’s
Hospital, Herston, Queensland, Australia
Correspondence: Mark A.F. Kendall, Delivery of Drugs and Genes Group, The
Australian Institute for Bioengineering and Nanotechnology, The University of
Queensland, Corner Cooper and College Road, St Lucia, Queensland 4072,
Australia. E-mail: m.kendall@uq.edu.au
Received 6 December 2013; revised 28 March 2014; accepted 1 April 2014;
accepted article preview onilne 8 April 2014; published online 8 May 2014
Abbreviations: DAMPs, damage-associated molecular patterns; FP, flat patch;
i.d., intradermal; i.m., intramuscular; MIP, maximum intensity projection; NP,
Nanopatch; SC, stratum corneum; VE, viable epidermis
& 2014 The Society for Investigative Dermatology www.jidonline.org 2361
responses generated by NP application by activating antigen
presenting cells to take up antigen.
Following Matzinger’s ‘‘danger hypothesis’’ (Matzinger,
1994), apoptotic and necrotic cells have been reported to
act as immunostimulants by releasing damage-associated
molecular patterns (DAMPs), enhancing cellular and
humoral immune responses to antigen (Kinsey et al., 2004;
Rovere-Querini et al., 2004; Kono and Rock, 2008; Green
et al., 2009; Marichal et al., 2011). Chemical adjuvants have
shown to induce cell death and danger signals upon
administration, which can act as strong endogenous
immunostimulatory agents (Yang et al., 2004a,b; Yang and
Shen, 2007; Marichal et al., 2011). Disruption of the
epidermis by scarification has also been demonstrated as
essential for the elicitation of the vaccinia virus–mediated
immunity and protection against challenge, whereas i.m.
delivery was not protective (Liu et al., 2010).
Here, we hypothesized that localized cell death caused by
NP-penetrating epidermal and dermal tissue would initiate a
cascade of events acting as a ‘‘natural immune enhancer’’,
mediated by the release of DAMPs concurrent with antigen
delivery. To test this hypothesis, we measured cell death
induced in situ by a conventional i.d. Mantoux injection and
compared it with NP. Systemic immunogenicity was com-
pared using delivered split virion influenza vaccine (Fluvax
(FV)). To our knowledge, this is the only quantitative and
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Figure 1. Comparison of the area of affect following NP application to skin and i.d. injection by hypodermic needle. (a) Size comparison of an NP next to a
31-G needle. (b) Scanning electron microscopy (SEM) image of a 31-G needle tip over NP projections (inset). Cryo-SEM images of murine skin of
(c) untreated ear, (d) following NP application, (e) 31-G needle i.d. in situ, (f) skin after 31-G needle removal following delivery of saline, and (g) bleb formation
following i.d. injection (20ml saline). Arrows depict the needle insertion site. (h) Coomassie Blue administered into mouse ears by either NP (left) or i.d.
injection (right). (i) Affected skin surfaces by Coomassie Blue measured in Image J (n¼ 18 applications each). Scale bar (a, g)¼ 1 mm, (b, e, f)¼ 200mm,
(c, d) 50mm. i.d., intradermal; NP, Nanopatch. Bars represent means±SD (***Po0.001).
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spatial study published investigating cell death induced by
skin immunization on immunogenicity.
RESULTS
Key physical differences in skin surface morphology following
NP application to and i.d. needle injection into skin
We examined the skin surface before and after NP and
31-G needle (hereafter referred to as needle) application
in vivo and ex vivo to gain insights into the skin perforation
induced by each device. Using scanning electron micro-
scopy, we measured the contact area between each device
and the skin surface (Figure 1b and d–f). Untreated murine ear
skin revealed an intact surface (Figure 1c), whereas NP
application produced microchannels, consistent with the
spacing of projections on an NP (Figure 1d), similar to
previous observations (Haq et al., 2009; Crichton et al.,
2010; Milewski et al., 2010). I.d. insertion of a needle
resulted in a single perforation at the needle insertion site
(Figure 1e and f, arrows), whereas saline delivery resulted in
the formation of a bleb (Figure 1g). The calculated contact
surface area between the skin and NP projections was
17.7±2.3 mm2 (n¼ 18), while 1.6±0.1 mm2 (n¼10) of the
needle tip made contact with the skin. Coating of Coomassie
Blue dye allowed visualization of microchannels inflicted by
NP, and confirmed coated payload delivery discretely into
each microchannel, where it had dissolved off the projection
upon application owing to rehydration within the skin
(Figure 1h, left). Coomassie Blue dye injected intradermally
allowed further visualization of the bleb (Figure 1h, right). The
affected skin area following NP application (Figure 1h inset
and i) measured 1.9±0.1 mm2, which was significantly less
than the delivery area of a needle: 27±11 mm2 (Po0.001;
Figure 1h and i). Combined, these data demonstrate significant
perforation of skin and discrete microchannel delivery after
NP application in contrast to a single i.d. delivery to a much
larger area in the form of a bleb when using a needle to inject
intradermally.
NP application to skin induces significantly higher and localized
cell death, compared with standard needle-based i.d. injection
We next examined and quantified cellular damage caused
within the skin by NP and i.d. injection over a 16-mm2 area
(an area equivalent to a single NP) by confocal laser scanning
microscopy and multiphoton microscopy (Figure 1e–g). We
freshly excised skin immediately after NP application or i.d.
injection of phosphate-buffered saline, and stained it with an
acridine orange and ethidium bromide cocktail to distinguish
live and dead cells, respectively (Figure 2a and b) (Raju et al.,
2006). Untreated skin contained 3.5±1.9% (n¼ 18) damaged
cells (Figure 2c). After NP application, 16.5±4.1% (n¼18) of
epithelial cells were dead (Figure 2c), significantly more than
untreated skin (Po0.0001). After NP application, dead cells
were restricted to a zone of up to 5-cell radii, or 26±13mm
(n¼ 81 projections), around each microchannel perforation
with interspersed viable cells. High levels of cell death were
observed where the edges of the NP interacted with the skin,
consistent with the theoretically modeled stress peaks at the
array boundaries (Meliga et al., 2013).
The cellular damage caused by i.d. injection of saline was
restricted to the individual needle perforation site (Figure 2a
and b), inducing 3.7±1.8% (n¼18) of dead cells, statistically
similar to untreated skin control. Cell death within the i.d.
bleb was similar in comparison with untreated control groups
(2.5±1.1%; P¼ 0.16, n¼ 5). Normalized against untreated
control groups, i.d. injection generated 65-fold fewer dead
cells than NP application. The area of dead cells within the
bleb area skin represented o0.5% of the total bleb area
(B0.07 mm2). Cross-sectional multiphoton microscopy
images demonstrated that damaged tissue in NP-treated
samples was mostly confined to the VE, whereas delivery by
needle resulted in cell death spread throughout the VE and
dermal layers (Figure 2b). The observed dead cells exhibited
predominantly necrotic characteristics, which was further
supported by the absence of apoptotic cell morphology (i.e.,
fragmented nuclei or crescent-shaped nuclei (Cobb et al.,
1996; Hotchkiss et al., 2009). Further morphological,
biochemical, and protein-based analyses are required to
further distinguish the cell death types. Collectively, these
data highlight key differences between the location of live/
dead cells and a delivered payload (e.g., vaccine).
Delivery of vaccine to skin by NP induces a significantly greater
antibody response than standard i.d. delivery by needle
With the local skin cell death and delivered payload profiles
quantified, we next compared the resultant systemic immune
responses elicited by NP and i.d. immunization routes
(Figure 3) by comparing antibody responses to FV spanning
three logs of delivered antigen doses. Endpoint titers from all
doses of FV tested were higher after NP delivery than those
elicited by i.d. delivery, with statistically significant differences
detected with delivered doses between 1 and 100 ng
(Figure 3). In addition, all mice given a dose of 5–100 ng
by NP seroconverted, and mean titers (10–100 ng) did not
differ statistically from those of the i.m. control group
(Supplementary Figure S1 online). In contrast, X50 ng of FV
delivered intradermally was required to achieve seroconver-
sion in all mice (Po0.001; Figure 3; Supplementary Figure S1
online). Together, these data demonstrated robust antibody
titers in mice immunized with NP-delivered FV, compared
with intradermally injected mice, illustrating a X10-fold
dose-sparing effect.
Colocalized NP-mediated skin damage, adjacent live cells, and
vaccine enhances systemic immunogenicity
From our immunogenicity results, we hypothesized that colo-
calization of antigen with NP-mediated skin damage adjacent
to live cells was a key contributing factor to enhanced
systemic immunogenicity. To test this hypothesis, we imaged
colocalization of NP-mediated skin damage in vivo, adjacent
to live cells with fluorescently labeled (Dylight 755) FV
antigen. Labeled antigen was administered by either NP or
i.d. injection, and animals were imaged within 5 minutes post
immunization in vivo to limit diffusion of the antigen (rain-
bow-colored; Figure 4). In NP-treated samples, 100% of dead
cells (orange) colocalized with fluorescently labeled antigen
by NP delivery, covering an area of 16 mm2. On the basis of
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the cell death profiles, Coomassie Blue data, and diffusion
profiles (Raphael et al., 2013), colocalization of antigen with
dead cells was much less pronounced with intradermally
delivered antigen (o0.5%), as indicated by the arrows
(Figure 4), suggesting lower colocalization of antigen with
dead cells (and therefore fewer DAMPs). These observations of
colocalizing cell death with antigen are consistent with our
previous results (Figures 1h and 2).
Although we identified that more antigen overlapped (co-
localized) with dead cells following NP than i.d. immuniza-
tions (Figure 4), it was not clear whether colocalization of
antigen with dead cells interspersed with live cells was
essential for enhanced antibody production. To explore this,
we compared antibody responses (10 ng FV) between mice
using NP, i.d. or with a combination, as depicted in
Figure 5a. In accordance with Figure 3, FV delivered by NP
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Figure 2. Cell viability in untreated, NP-treated, and i.d. saline-injected murine skin. Acridine orange and ethidium bromide were used to differentiate
between live (green) and dead (magenta) cells. (a) Multiphoton microscopy images of untreated, NP-treated, and i.d. treated murine ears with high
corresponding magnification insets. (b) Representative side views of a with collagen (blue, second harmonic generation). (c) Quantification of cell viability per
16 mm2; skin incubated in methanol before staining as positive cell death control (Skala et al., 2005). Original magnification 10 and  40. White arrow
depicts i.d. injection site. Results are representative of three independent experiments with n¼ 5–8 replicates and up to 3 measurements per replicate.
Scale bar (a, upper panels)¼ 1 mm, (a, lower panels and b)¼ 200mm. D, dermis; i.d., intradermal; MIP, maximum-intensity projection; NP, Nanopatch;
SC, stratum corneum; VE, viable epidermis. Error bars represent means±SD (***Po0.0001).
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elicited higher antibody responses than that delivered intra-
dermally (Figure 5b; Po0.05). Application of an NP or an FP
(inducing B3.8% of cell death; Supplementary Figure S2
online) immediately before intradermally delivered FV did not
enhance the resultant immunogenicity beyond that obtained
with i.d. delivery of FV alone. We interpret this result as
follows: colocalization of tissue damage caused by NP with
antigen is important for enhanced immunogenicity. Similar
results were obtained when repeated with a 1 ng FV dose
(Supplementary Figure S3 online). Taken together with the
results in Figure 4, these data demonstrated that colocalization
of antigen with NP-induced cellular damage correlated with
enhanced immunogenicity of NP-delivered FV.
As i.d. injections resulted in B14-fold larger antigen
delivery area than NP (Figure 1h and i), we then evaluated
whether altering i.d. injection volumes and hence concentra-
tions/ area while maintaining the same delivered dose (5 ng)
may affect the systemic immunogenicity. Five ng were
administered in different volumes (5–50ml). The highest
concentration tested was similar to the concentration of a
dry-coated NP (2.5 ngml 1). This difference in antigen con-
centration did not affect immunogenicity (data not shown).
Antigen-specific endpoint titers did not significantly differ
between any i.d. groups (P40.05; Figure 5c). These results
indicated that vaccine concentration (ranging
1–0.1 ngml 1) did not affect the immunogenicity in i.d.
immunizations.
To further examine the correlation between cell death and
enhanced immunogenicity, we extended NP conditions to
provide lower and higher levels of cell death—by changing
the number of projections cm 2 while maintaining all other
parameters constant, including the delivered dose (assessed as
previously described, Fernando et al., 2012). Cell death was
quantified while influenza-specific immunoglobulin G was
measured after delivering 1 ng of FV by NP of varying
projections cm 2 (ranging from 10,000, 21,000 to 3
21,000) or by i.d. injection. As expected, cell death
increased with increasing numbers of projections cm 2
almost linearly (R2¼0.89), resulting in 2.3±1.0% (untreated),
3.1±1.0% (i.d.), 8.1±1.1% (10,000), 16.2±1.7% (21,000),
or 45.4±4.0% (321,000 projections cm2) (Figure 5d–f
left). This indicated that the localized cell death per projection
was consistent. Figure 5f (right) illustrated that increased cell
death correlated with increased immune responses, with one
notable exception: extending to the highest level of cell death
(induced by 3 21,000 NP projections cm 2) led to a
significant decrease (P¼0.0074) in antibody response com-
pared with a single NP with 21,000 projections.
DISCUSSION
Several different mechanical methods exist for delivering
vaccines into skin, such as either needle-based or needle-free
approaches (Kis et al., 2012; Kim et al., 2012a,b). The delivery
of conventional protein-based and live viral vaccines using
these devices has resulted in comparable systemic immune
responses to those achieved by standard i.d. injection (Carey
et al., 2011; Hung et al., 2012b; Kim et al., 2012b). Here, we
compared the application of two transcutaneous immuni-
zation devices into skin. We used either NP, standard
needle-based i.d. injection, or combinations of both
methods, and quantified the resultant cell death (including
magnitude and location within skin) and the systemic
immunogenicity generated by influenza vaccination.
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Figure 4. Colocalization of antigen with live and dead cells using Dylight
755-labeled FV and viability stain. In vivo imaging of fluorescent Dylight 755-
labeled FV administered by NP or i.d., and dead cells (orange) 5 min post
administration, detected using a MS FX Pro system overlaid with X-rays (gray
scale). Images are representative of n¼3 replicates/group. White arrows depict
i.d. injection sites. EB, ethidium bromide; FV, Fluvax; i.d., intradermal; NP,
Nanopatch. Color-coded Dylight 755 fluorescence represents intensity ranging
from high (white-red) to low (blue-black).
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Overall, we found that NP immunization consistently
produced higher antibody titers than standard needle-based
i.d. immunizations, which correlated with higher cell death
levels after NP than i.d. injections. We propose that the
observed improved immunogenicity in NP groups is linked
to antigen colocalizing within defined areas of live cells
adjacent to dead cells within epidermal and dermal tissue
(Figure 4); this was not seen with i.d. injection.
The concept that cell death or co-delivering dead cells with
antigens enhances immunogenicity is well established (Kinsey
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Figure 5. Immune responses to Fluvax following different levels of induced cell death. (a) Schematic of applied immunizations. (b) Fluvax (10 ng) was delivered
by coated NP, i.d., or a combination (i.d. vaccine delivery followed by NP or FP) into murine ears (control group i.m. 6,000 ng). (c) Various FV concentrations
administered intradermally did not affect immunogenicity following i.d. immunization, delivering a total of 5 ng of Fluvax. (d) Confocal laser scanning microscopy
and (e) MPM imaging of cell death post NP application using various densities (10,000; 21,000; 321,000 projections cm2). (f) Quantification of cell death
linked to Fluvax immunogenicity (1 ng). All samples were analyzed as previously described. Scale bar (d)¼ 1 mm, (e)¼50mm. FP, flat patch; FV, Fluvax; i.d.,
intradermal; i.m., intramuscular; NP, Nanopatch. Depicted are means with n¼5 (NS: not significant (P40.05),*Po0.05, ***Po0.001, ****Po0.0001).
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et al., 2004; Rovere-Querini et al., 2004; Kojima et al., 2007;
Kono and Rock, 2008; Green et al., 2009). Similarly, others
found that DNA released by dead cells mediates the
adjuvanticity of aluminium salts (Marichal et al., 2011).
Increasing the number of NP projections penetrating the skin
and thus increasing localized cell death led to improved
immunogenicity, until a plateau was reached, after which the
immunogenicity decreased (Figure 5d–f). This type of curve is
homologous to dose ranging versus immunogenicity that
shows similarity with titration curves of chemical adjuvant
doses (unpublished observations and Ng et al., 2012). A key
difference, however, is that in our study we propose that the
immune-enhancing effect is generated by the mechanical
stimulus of the NP being applied to the skin, generating
localized cell death.
Recently, laser-based adjuvantation has gained interest as a
potential immune enhancer (Chen et al., 2010) that has
worked synergistically with other chemical adjuvants (Chen
et al., 2012). A ‘‘physical adjuvantation effect’’ of the laser
was stipulated (Chen et al., 2013). In agreement with our
study, colocalization of the laser beam and immunization site
was essential for enhanced immunogenicity. We speculate
that laser-induced cell damage/ death (and associated DAMP
release) colocalized with antigen and thus enhanced
immunogenicity similar to the synergistic effect with
chemical adjuvants. A key difference in our study in
comparison with that of others was, however,
that the immune enhancer effect was generated by the NP
application itself, generating localized cell death. I.d. injection
generated significantly lower cell death; therefore, DAMPs
may have colocalized less with antigen and live cells; this is
summarized schematically in Figure 6a. With live cells
immediately adjacent to dead cells sensing danger signals
and chemokine/ cytokine gradients required for their activa-
tion, and with interspersed vaccine, these live cells may be
considered as the target cells to which antigen should be
delivered to for enhanced immune responses. Therefore, we
believe that a certain threshold of cell death is beneficial to
augment immunogenicity to an antigen, beyond which cell
death becomes detrimental. This would further support the
hypothesis of the NP-induced cell death acting as ‘‘natural
immune enhancer’’ contributing to enhanced immunogeni-
city, compared with standard i.d. injection.
The markedly lower cell death after i.d. injection was
localized to a single needle insertion site. Previous investiga-
tions of skin cell death induced by mechanical vaccine
delivery devices such as tattooing devices were reported to
induce necrosis and inflammatory cell infiltration (Gopee
et al., 2005) with increased cellular and humoral immune
responses (Pokorna´ et al., 2008). Further, ballistic delivery of
microparticles found 490% dead cells in the center of the
target site, with only the skin target periphery containing both
live/ dead cells (Raju et al., 2006). Our experimental findings
contrast Raju and colleagues’ findings most likely because
of the inherently different device and application velocities
(2.3 vs.4100 m s 1). However, our experimental findings are
consistent with our modeled stress-contours induced by NP
application to skin (Figure 6b), where cell death and highest
simulated stress levels (red) overlap at the site of projections
penetrating the skin (applying previously published mechan-
ical models; Meliga et al., 2013). Qualitative comparison of
the spatial distributions of theoretical stress with measured cell
death suggests that cells die in regions where Von-Mises
stresses of at least 1–10 MPa are generated, subject to model-
ing assumptions (Meliga et al., 2013). This is the only time that
skin cell death has been linked to stress distribution and
magnitude to our knowledge.
The type of induced cell death is likely to be important, as
necrotic cells are generally more immunogenic than apoptotic
cells (Rock and Kono, 2008). We speculate that the visualized
dead cells are predominantly of necrotic origin, which is in
agreement with Gopee et al. (2005), who observed necrotic
cell death following tattooing in skin. Necrotic cell death is
further supported by the dynamic application of the NP-
generating instantaneous stresses and stress-induced trauma
in Figure 6b (detailed analysis on the stresses in Meliga et al.,
2013) and the absence of apoptotic cell characteristics (Cobb
et al., 1996; Hotchkiss et al., 2009) post NP/ i.d. application.
Further studies are required to definitively distinguish the type
of cell death.
In conclusion, our work herein proposes that physically
induced cell death by an immunization device co-delivering
antigen into the skin can significantly improve the immuno-
genicity of vaccines by physical immune enhancement. This is
a significant departure from the current adjuvant paradigm,
generated by chemical or biological reagents added to anti-
gens to enhance immune responses that are delivered into the
body.
MATERIALS AND METHODS
Materials
Seasonal human trivalent influenza vaccine (Fluvax 2010) was
manufactured by CSL Limited (Parkville, Australia), containing 15mg
of hemagglutinin per strain per dose of purified, inactivated,
detergent-disrupted split virion influenza virus with antigen of the
following strains: A/California/7/2009, A/Wisconsin/15/2009, and
B/Brisbane/60/2008.
Mice
Female 6- to 8-week-old BALB/c or C57BL/6J mice were obtained
from the Australian Research Council (Perth, WA). Anesthesia was
performed by intraperitoneal injection of ketamine and xylazil
anesthetic (50 and 10 mg kg 1; Troy laboratories, Smithfield, Aus-
tralia) before immunizations. Mice were killed by cervical dislocation
either immediately or at indicated time points after treatment. All
animal experiments were conducted according to the University of
Queensland Anatomical Biosciences Ethics Committee regulations.
Immunizations
The NP was fabricated from silicon using a deep reactive ion etching
process at the University of Queensland (Jenkins et al., 2012). Coating
solutions for NP were prepared as previously described (Chen et al.,
2009, 2011), with coated projections examined by scanning electron
microscopy and delivery efficiency verified (Fernando et al., 2012).
The NP was applied using a spring-loaded applicator (Crichton et al.,
2010) at B2.3±0.2 m s 1 and applied for 2 minutes. NP and i.d.
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injections (31-G, 20ml) were administered into the ventral site of
murine ears, whereas i.m. injections were given into both hind legs
into the caudal thigh muscle (29-G; 33ml).
Viability staining of tissue
To discriminate between live and dead cells, a mixture of metachro-
matic acridine orange and ethidium bromide (both Fluka, Steinheim,
Germany) in phosphate-buffered saline was used (Franklin and
Locker, 1981; Raju et al., 2006). Acridine orange and ethidium
bromide are routinely used to discriminate between live and dead
cells in cell suspensions and tissue by intercalating with DNA and
RNA (Darzynkiewicz et al., 1992; Baskic et al., 2006). Tissues were
split at the dermis–cartilage–dermis junction, with cartilage carefully
removed before staining in acridine orange (0.03mg ml 1) and
ethidium bromide (0.1mg ml 1). Positive controls for cell death were
pretreated with ice-cold methanol before staining (Skala et al., 2005).
Intradermal injection
a
b
Nanopatch
Colocalization Colocalization
Dead cells
DAMPs
Vaccine
200 µm
30 µm
VM stress
(MPa)
+7.2e+01
+2.2e+01
+1.0e+01
+4.7e+00
+2.2e+00
+1.0e+00
+4.7e–01
+2.2e–01
+1.0e–01
+4.7e–02
+2.2e–02
+1.0e–02
+4.7e–02
+2.2e–02
+1.0e–02
Stress simulation
Live cells
Dead cells
Experimental data
50 µm
SC
VE
Dermis
Live cells
Figure 6. Schematic of i.d. injection and NP delivery alongside live and dead cells, vaccine, and proposed DAMP release and comparison of induced cell death
with theoretical stresses in skin. (a) Vaccine (blue) administered either by i.d. injection or dissolving off coated NP projections with dead cells (magenta). Vaccine
was found predominantly around the i.d. insertion site within the VE and the dermis, causing a bleb formation with minimal colocalization of DAMPs (magenta
stars) with vaccine and viable cells (green). NP induces highly localized cell death in the VE and minimally in the dermis, with colocalization of DAMPs with
antigen and live cells. (b) Comparison of measured cell death with theoretical stresses induced in skin by NP application. Bar (a, upper panel)¼200mm, (a, lower
panel)¼30mm, (b)¼ 50mm. DAMPs, damage-associated molecular patterns; i.d., intradermal; NP, Nanopatch; SC, stratum corneum; VE, viable epidermis;
VM, Von-Mises.
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Confocal and multiphoton microscopy was used for visualization
purposes.
For the full methods, please refer to Supplementary Information
online.
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